Numab Therapeutics AG. (1/13/21). "Press Release: Numab Therapeutics and Kaken Pharmaceutical Form Co-Development Alliance for a Next-Generation Atopic Dermatitis Treatment Option". Wädenswil (Zurich).

	Region	Asia
	Organisation	Numab Therapeutics AG
	Group	Numab (Group)
	Organisation 2	Kaken Pharmaceutical Co., Ltd. (TSE: 4521)
	Product	NM26-2198 trispecific antibody (Numab)
	Product 2	dermatic
	Index term	Kaken Pharmaceutical–Numab: therapeutic antibody, 201706– collab + license option €na for multispecific antibody for inflammatory disease
	Person	Urech, David (Numab 201910 CEO + Co-Founder before Esbatech 2004–2010)
	Person 2	Rufo, Caroline (MacDougall 202003)

Kaken to fund global preclinical and early clinical development of multispecific antibody NM26-2198 in exchange for commercial rights in key Asian markets

Numab Therapeutics AG today announced the formation of a global co-development and regional licensing agreement with Kaken Pharmaceutical for the company’s novel multispecific anti-inflammatory drug candidate NM26-2198, which blocks three key pathways in the pathophysiology of atopic dermatitis. The alliance builds on a collaboration and option agreement established in 2017.

Under the expanded agreement, Kaken receives commercial rights for NM26-2198 in Japan, China, South Korea, Taiwan, Singapore, and Hong Kong, while Numab retains the commercial rights to the US, Europe, and the rest of the world. The parties will jointly develop NM26-2198 with Kaken covering the majority of global development costs up to clinical proof-of-concept. Upon successful commercialization of products resulting from the alliance, Kaken will receive certain payments from Numab up to a cap that is calculated based on previous R&D payments made by Kaken to Numab.

“Today’s news puts our second proprietary key pipeline asset NM26-2198 on a very promising path for value generation and accelerated global development. The alliance with Kaken Pharmaceutical is in line with our Asia regional partnering strategy and follows the structure of our previous deal with CStone Pharmaceutical on our lead oncology asset NM21-1480,” said David Urech, Ph.D., Founder and Chief Executive Officer of Numab Therapeutics.

About Numab Therapeutics

Numab Therapeutics is an oncology-focused biopharmaceutical company based in Zurich-area, Switzerland. At Numab, we are writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. With our proprietary MATCH technology platform, we are fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind. Our lead product was designed to balance potent anti-tumor immunity with a desirable safety profile by targeting 4-1BB, PD-L1 and Human Serum Albumin simultaneously. We believe meeting the highest quality standards in every step of the drug design process matters and will result in better patient outcomes. For further information, visit www.numab.com.

About KakenPharmaceutical

Kaken Pharmaceutical Co., Ltd. (KAKEN) is a specialty pharmaceutical company in Japan with strong experience in developing and commercializing novel pharmaceuticals and medical devices in the fields of orthopedics and dermatology.

KAKEN concentrates its R&D resources in areas such as the immune system, the nervous system, and infectious diseases.

KAKEN’s ongoing quest is to Bringing Smiles to Everyone. For this purpose, KAKEN strives to improve the quality of life of patients through the development and distribution of superior pharmaceuticals. For further information, visit http://www.kaken.co.jp.

Contacts:

For Numab Therapeutics
David Urech
Chief Executive Officer
[email protected]

For media
MacDougall
Sara Michelmore or Caroline Rufo, PhD.
+1 781-235-3060
[email protected]

Record changed: 2023-06-05